Throughout 2023, we at Angioedema News have been bringing you coverage of the latest news related to angioedema, from basic research to clinical trials and advances in treatment. Here we’ve compiled a list of the top 10 most-read articles we’ve published this past year. We look forward to…
News
Preventive treatment with Orladeyo (berotralstat) was associated with improved treatment satisfaction among hereditary angioedema (HAE) patients who had switched from injectable therapies, according to a recent clinical trial analysis. BioCryst Pharmaceutical’s oral treatment also was well tolerated and associated with low HAE attack rates, as has been…
People with hereditary angioedema (HAE) who switched from long-term androgen treatment to BioCryst Pharmaceuticals’ Orladeyo (berotralstat) saw a reduction in the number of swelling attacks. That’s according to a new analysis of data from patients who discontinued androgens less than 60 days (two months) before entering APeX-S…
Long-term prophylaxis, or preventive treatment, with Orladeyo (berotralstat) is well tolerated, and results in sustained reductions in swelling attacks and gains in quality of life in adolescents and adults with hereditary angioedema (HAE). That’s according to nearly two years of data from the completed Phase 3 APeX-2…
The monthly under-the-skin injection therapy garadacimab will be considered for approval for treating hereditary angioedema (HAE) in both the U.S. and the European Union. Developer CSL Behring announced that both the U.S. Food and Drug Administration and the European Medicines Agency have agreed to review applications of the therapy…
Adding a short-term regimen of C1-INH concentrate to the preventive treatment of a 63-year-old man with hereditary angioedema (HAE) enabled a successful tooth extraction without a swelling attack in his larynx, a case study reports. The tailored Orladeyo (berotralstat) prophylaxis regimen was designed to prevent an attack…
Prophylactic, or preventive, treatment with deucrictibant significantly reduced the rate of swelling attacks among adults with hereditary angioedema (HAE) in a Phase 2 clinical trial. “These study results, together with the compelling data from our on-demand program, further strengthens our confidence that deucrictibant can become the preferred option…
Argentina’s regulatory body has approved BioCryst Pharmaceuticals’ Orladeyo (berotralstat) to prevent swelling attacks in adults and adolescents, ages 12 and older, who have hereditary angioedema (HAE). The decision by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) comes a few months after the approval of…
The Phase 3 KONFIDENT trial, which is testing oral sebetralstat as an on-demand treatment for hereditary angioedema (HAE), has achieved its targeted number of on-treatment swelling attacks. The trial can wrap up now that three attacks per patient were treated. Topline data is expected in early 2024. If…
A single subcutaneous or under-the-skin injection of STAR-0215 — an experimental treatment that aims to prevent swelling attacks in people with hereditary angioedema (HAE) — led to a sustained decrease in kallikrein protein activity in healthy adults for close to three months, according to new trial data. Early…
Recent Posts
- Extended-release tablets shown to cut HAE swelling attacks by over 80%
- Using my voice to advocate has brought me places I never expected
- Angioedema recurred in lupus despite normal C1-INH, case report finds
- FDA to decide by March on approval for 1-time gene-editing treatment for HAE
- As Rosh Hashanah approaches, I’m happy for a new beginning